New study first ever to directly compare once-daily Levemir® with another basal insulin analogue
- Details
- Category: Novo Nordisk
Novo Nordisk has announced the first patient visit in a new head-to-head clinical trial of once-daily Levemir® against insulin glargine. This study is the first time the two basal insulins will be directly compared in an exclusively once-daily regimen. Outcomes measured in the study will include efficacy, effect on weight and hypoglycaemia in type 2 diabetes patients.
Genzyme Completes Transaction with Bayer HealthCare
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath®/MabCampath® (alemtuzumab), giving Genzyme primary responsibility for the development and commercialization of this promising multiple sclerosis (MS) therapeutic candidate. Genzyme is conducting two rapidly progressing phase 3 studies of alemtuzumab in relapsing-remitting MS patients.
AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration
- Details
- Category: AstraZeneca
AstraZeneca and Merck & Co., Inc. will collaboration to research a novel combination anticancer regimen composed of two investigational compounds, MK-2206 from Merck and AZD6244 (ARRY-886*) from AstraZeneca. Preclinical evidence indicates that combined administration of these compounds could enhance their anticancer properties.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments.
Abbott Named One of the Top 10 Companies for Scientists
- Details
- Category: Abbott
Abbott was recently named one of the Top 10 companies on The Scientist magazine's "Best Places to Work in Industry" list. Abbott was ranked No. 6 on the list of Large Companies (more than 5,000 employees). This is the sixth time that Abbott has been on the list since The Scientist first started ranking companies in 2003. This prestigious list is based on a detailed survey of scientists at life-science companies and research institutions worldwide.
AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder
- Details
- Category: AstraZeneca
AstraZeneca today announced that the company has referred its application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of recurrent depressive episodes in adult patients with major depressive disorder (MDD) to the Committee for Medicinal Products for Human Use (CHMP; a scientific committee of the European Medicines Agency, EMEA).
More Pharma News ...
- Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva®
- Nycomed Reports a Solid Start to 2009
- US Department of Health and Human Services (HHS) purchases GSK's A (H1N1) influenza antigen
- Roche announces new two-year data from the LITHE study
- Sandoz to acquire EBEWE Pharma specialty generics business
- Abbott's XIENCE V(R) Demonstrates Impressive Results in SPIRIT V Study
- Pfizer Expands Its Generics Portfolio